FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling
This article was originally published in The Tan Sheet
Executive Summary
FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.
You may also be interested in...
FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda
FDA’s Nonprescription Drug Advisory Committee will consider proposed tests for evaluating the safety of sunscreen ingredients that sponsors want to add to the OTC monograph. The committee will not consider the safety or efficacy of specific ingredients pending review via TEAs.
FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda
FDA’s Nonprescription Drug Advisory Committee will consider proposed tests for evaluating the safety of sunscreen ingredients that sponsors want to add to the OTC monograph. The committee will not consider the safety or efficacy of specific ingredients pending review via TEAs.
Industry Cost Estimates For Proposed Consumer Antiseptic Rule Dwarf FDA’s
The Personal Care Products Council and American Cleaning Institute challenge FDA cost projections and question the agency’s proposal for clinical studies data to back the efficacy of antibacterial hand-wash products. The groups say manufacturers require guidance and request an extension of the deadline for data submissions, currently December 2014.